CMR Green Technologies Ltd IPO: Key Details and Company Overview CMR Green Technologies Limited is set to launch its initial public offering (IPO), with details on allotment status, listing date, and pricing now available. The IPO, which is structured as an offer-for-sale (OFS), does not generate proceeds for the company. Instead, the net proceeds will be distributed to promoter selling shareholders in proportion to their share offerings. The primary goal of the IPO is to enhance the company’s visibility, brand recognition, and liquidity for existing shareholders, while creating a public market for its shares. The IPO subscription rates for different investor categories are as follows: Qualified Institutional Buyers (QIBs) have a subscription rate of 9.87x, Non-Institutional Investors (NIIs) at 85.46x, and Retail Individual Investors (RIIs) at 15.79x. As of June 5, 2026, at 4:31 PM, the funds have been unblocked or debited, though the tentative listing date has not been officially disclosed. CMR Green Technologies operates in the recycling of non-ferrous metals and the manufacturing of recycled aluminium alloys and other metal products. Its production includes recycled aluminium alloys in ingot and liquid form, aluminium billets, zinc alloy ingots, and segregated furnace-ready scrap of stainless steel, copper, brass, zinc, lead, and magnesium. The company supplies these products primarily to automotive original equipment manufacturers (OEMs), Tier 1 automotive suppliers, and industrial customers. Additionally, it processes used beverage can scrap for recycling and provides liquid aluminium to automotive and industrial sectors.#icra #cmr_green_technologies_ltd #toyota_tsusho_corporation #nikkei_mc_aluminium #nippon_light_metal
Wockhardt Stock Surges 19% Amid FDA Approval for Novel Antibiotic Wockhardt's stock price surged 19% on Monday, hitting an all-time high of ₹2,420 on the BSE, following the company's announcement of U.S. Food and Drug Administration (FDA) approval for Zaynich, a novel intravenous antibiotic. The stock also rallied 75% over the past month, outperforming the BSE Sensex's 3% decline. The approval, which came after a significant rise in trading volumes, marks a pivotal moment for the pharmaceutical company, positioning it as a leader in the fight against antimicrobial resistance. Zaynich, a combination of cefepime and zidebactam, is designed to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. The drug targets a critical market, as over 2.8 million antimicrobial-resistant infections occur annually in the U.S., causing more than 35,000 deaths. cUTIs alone account for over 600,000 hospitalizations each year, underscoring the drug's potential to address a significant unmet medical need. The FDA's approval is expected to unlock a $9 billion market opportunity in the U.S. alone, with ICICI Securities highlighting its transformative impact on Wockhardt's profitability. The approval of Zaynich is particularly notable as it represents the first new chemical entity (NCE) fully developed and commercialized by an Indian pharmaceutical company to receive U.S. FDA approval. Wockhardt's pipeline includes six antibiotics in various stages of development, with three targeting Gram-Negative pathogens and three targeting Gram-Positive bacteria. All six drugs have been granted Qualified Infectious Disease Product (QIDP) designation by the FDA, accelerating their development and enhancing their commercial prospects. Wockhardt's financial performance has also strengthened, with the company reporting a 12.#fda #icici_securities #ockhardt #zaynich #icra
